Bioventix has completed a US$1.4 million sell-down of founder’s equity
Bioventix Plc has raised funds through a sell-down of the founder’s equity.
Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.
Talk to the deal team
Related deals
AMC Media Group has been acquired by Formedics
AMC Media Group, a healthcare professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician’s Weekly and OncWeekly.
Learn moreBellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Learn moreUnitary Healthcare has been acquired by Axel Health
Axel Health Oy, headquartered in Finland, has acquired the Finnish software company Unitary Healthcare Oy.
Learn more